Infliximab in ulcerative colitis

Abstract

Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn's disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the effi cacy of infliximab in the treatment of moderate to severe UC. © 2008 Dove Medical Press Limited. All rights reserved.